A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS
Pfizer
Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients. This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery. All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * 18 years of age or older * Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastat…
Interventions
- DrugPF-08165784
Taken by mouth (PO)
- DrugFulvestrant
Selective Estrogen Receptor Degrader (SERD)
- DrugAtirmociclib
Selective CDK4 inhibitor
- DrugCetuximab
Monoclonal antibody (EGFR inhibitor)
- DrugLetrozole
Nonsteroidal aromatase inhibitor
Locations (5)
- Highlands Oncology Group, PAFayetteville, Arkansas
- Highlands Oncology Group, PARogers, Arkansas
- Highlands Oncology Group, PASpringdale, Arkansas
- START Midwest, LLCGrand Rapids, Michigan
- Pan American Center for Oncology Trials, LLC- Hospital Oncológico OfficeSan Juan